Overhaul of UK medicines legislation gets under way
This article was originally published in SRA
Executive Summary
The UK’s Medicines and Healthcare products Regulatory Agency has begun a three-year project to consolidate and review the national medicines legislation1. The Medicines Act 1968 has been expanded and changed so many times over the past 40 years that it is now a “very complex and fragmented set of legal provisions which are unwieldy to use and complicated to explain or understand”, says the agency. Some of the provisions may no longer be fit for purpose and may contradict current European Union-driven regulation, it adds.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.
EMA To Get The Ball Rolling On Making CTIS Global
The European Medicines Agency wants to further improve the visibility of data in the Clinical Trials Information System by establishing it as a World Health Organization primary registry.